MM1: Emergency Use Authorization of Remdesivir for Patients With Confirmed or Suspected COVID-19

Expert faculty discuss ways to improve the empiric treatment of HABP/VABP in the ICU in this commentary from Clinical Care Options (CCO)

Marion Elligsen, BScPhm, MSc, RPh, ACPR Keith S. Kaye, MD, MPH Andrew Shorr, MD, MPH, MBA Released: November 18, 2022

Learn from experts about strategies to improve timely, effective antibiotic therapy in patients with HABP/VABP at risk for multidrug resistance, from Clinical Care Options (CCO)

Marion Elligsen, BScPhm, MSc, RPh, ACPR Keith S. Kaye, MD, MPH Andrew Shorr, MD, MPH, MBA Released: November 16, 2022

Introduction

Strategies for Empiric Therapy in HABP/VABP

Key Aspects of Antimicrobial Resistance in HABP/VABP

Strategies for Effective Antimicrobial Resistance Risk Stratification

Question and Answer Session

Hear experts discuss ExPEC burden, populations at risk and potential vaccines to reduce invasive disease and antibiotic resistance, from Clinical Care Options (CCO).

Lilian Abbo, MD, FIDSA
Program Director Julie Ann Justo, PharmD, MS David Van Duin, MD, PhD, FIDSA, FAST Released: November 3, 2022

All Eyes on ExPEC: Introduction

ExPEC: A Cause for Concern

ExPEC: Who’s at Risk?

Great ExPEC’tations: A Path to Reducing Antimicrobial Resistance

Clinical Care Options (CCO) presents expert faculty discussing RSV in certain adult populations and the development of RSV vaccines

John J. Russell, MD, FAAFP
Program Director Laura Hurley, MD, MPH Pamela Rockwell, DO, FAAFP Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Registered Nurses: 1.5 Nursing contact hours Released: October 28, 2022 Expired: October 27, 2023